Exelixis And Ipsen Announce Results From Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib In Combination With Atezolizumab In Metastatic Castration-Resistant Prostate Cancer
Portfolio Pulse from Benzinga Newsdesk
Exelixis and Ipsen have announced results from their Phase 3 CONTACT-02 trial, which evaluated the combination of Cabozantinib and Atezolizumab in treating metastatic castration-resistant prostate cancer.
August 21, 2023 | 5:27 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Exelixis, a co-developer of the drug combination evaluated in the CONTACT-02 trial, could see stock price changes based on the trial results.
The results of the trial could have a significant impact on Exelixis' stock price. Positive results could boost investor confidence, while negative results could lead to a drop in stock price. However, without specific details on the trial results, it's difficult to predict the direction of the impact.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
Ipsen, a co-developer of the drug combination evaluated in the CONTACT-02 trial, could see stock price changes based on the trial results.
The results of the trial could have a significant impact on Ipsen's stock price. Positive results could boost investor confidence, while negative results could lead to a drop in stock price. However, without specific details on the trial results, it's difficult to predict the direction of the impact.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100